Novo Nordisk (NOV) Price & Analysis

Compare

485 Followers

NOV Stock Chart & Stats

Day’s Range― - ―

52-Week Range€38.54 - €125.12

Previous CloseN/A

Volume21.06K

Average Volume (3M)557.82K

Market Cap

kr205.71B

Enterprise Value€2.04T

Total Cash (Recent Filing)kr41.55B

Total Debt (Recent Filing)kr118.72B

Price to Earnings (P/E)14.0

Beta0.72

Next Earnings

Nov 05, 2025

EPS Estimate

0.74

Last Dividend Ex-Date

Aug 15, 2025

Dividend Yield3.3%

Share Statistics

EPS (TTM)0.80

Shares Outstanding3,390,128,000

10 Day Avg. Volume299,275

30 Day Avg. Volume557,824

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

kr61.96

Price Target Upside32.78% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering14

Bulls Say, Bears Say

Bulls Say

Growth OpportunitiesThe oral Sema launch in FY26 is believed to be underappreciated, potentially providing an additional growth opportunity for Novo Nordisk.

Product MixMore visibility on product mix with positive impact related to 340B, mostly from Ozempic with remainder being insulin, which explains NovoRapid and Tresiba beats.

ValuationAnalyst recommends maintaining a Buy rating on Novo Nordisk due to its valuation, with the company trading at a c10-year low on PE despite continued forward double-digit sales CAGR.

Bears Say

Financial PerformanceNovo announced an EBIT guide cut on restructuring costs, with the guide range lowered significantly, making the net benefit unclear.

Market PositionNovo is no longer viewed as a 'premium' growth company, and there is increasing debate around the correct trading PE multiple as it approaches the sema patent cliff.

Sales OutlookThere is a risk of a top-end sales guide cut for FY25, with implications continuing into FY26, due to disappointing sales trajectories.

Novo Nordisk News

Mixed options sentiment in Novo Nordisk with shares up 1.15%

Mixed options sentiment in Novo Nordisk (NVO), with shares up 62c, or 1.15%, near $54.92. Options volume relatively...

2d ago

NVO

Microsoft, OpenAI sign MOU for next phase of partnership: Morning Buzz

The major averages were mixed near noon as investors prepare for next week’s Federal Reserve meeting. The recent...

2d ago

Novo Nordisk tells workers to return to office, Bloomberg reports

Novo Nordisk (NVO) CEO Maziar Mike Doustdar is calling workers back to the office as the Ozempic maker...

2d ago

LLY

NVO

Oracle surges on cloud outlook, Novo to cut 9,000 jobs: Morning Buzz

The major averages were mixed near noon following Oracle’s quarterly report, in which the cloud computing giant provided...

4d ago

ATI

HPQ

Another Novo Nordisk profit warning ‘still possible,’ says BofA

After Novo Nordisk (NVO) announced an EBIT guide cut on restructuring costs, with the EBIT growth guidance range...

4d ago

NVO

Novo Nordisk lowers operating profit growth outlook for 2025 to 4%-10%

After Novo Nordisk (NVO) announced a company-wide transformation and said it intends to reduce the global workforce by...

4d ago

NVO

Novo Nordisk to reduce workforce by 9,000 positions

Novo Nordisk (NVO) announced a company-wide transformation to simplify its organization and reallocate resources towards the company’s opportunities...

4d ago

NVO

Bernstein upgrades Novo Nordisk with market ‘fully capitulated’

Bernstein analyst Florent Cespedes upgraded Novo Nordisk (NVO) to Outperform from Market Perform with a price target of...

5d ago

NVO

Novo Nordisk upgraded to Outperform from Market Perform at Bernstein

Bernstein upgraded Novo Nordisk (NVO) to Outperform from Market Perform. Published first on TheFly – the ultimate source...

5d ago

NVO

ICER update on GLP-1s a ‘win’ for Eli Lilly, says BofA

BofA notes that the Institute for Clinical and Economic Review released its updated draft report for obesity drugs...

5d ago

LLY

NVO

Hold Rating for Novo Nordisk Amid Restructuring and Market Challenges

Analyst Sachin Jain of Bank of America Securities maintained a Hold rating on Novo Nordisk, with a price...

3d ago

NVO

Novo Nordisk’s Strategic Restructuring Faces Uncertainty Amid Competitive Pressures

In a report released today, Evan Seigerman from BMO Capital maintained a Hold rating on Novo Nordisk, with...

4d ago

NVO

Novo Nordisk’s Strategic Focus on Obesity Market and Oral Semaglutide Drives Buy Rating

In a report released today, Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk, with...

26d ago

NVO

Novo Nordisk Faces Uncertainty Amid Revenue Guidance Adjustment and Leadership Transition

BMO Capital analyst Evan Seigerman maintained a Hold rating on Novo Nordisk today and set a price target...

1M ago

NVO

NOV FAQ

What was Novo Nordisk’s price range in the past 12 months?

Novo Nordisk lowest stock price was €38.54 and its highest was €125.12 in the past 12 months.

What is Novo Nordisk’s market cap?

Novo Nordisk’s market cap is kr205.71B.

When is Novo Nordisk’s upcoming earnings report date?

Novo Nordisk’s upcoming earnings report date is Nov 05, 2025 which is in 52 days.

How were Novo Nordisk’s earnings last quarter?

Novo Nordisk released its earnings results on Aug 06, 2025. The company reported €0.798 earnings per share for the quarter, beating the consensus estimate of €0.795 by €0.004.

Is Novo Nordisk overvalued?

According to Wall Street analysts Novo Nordisk’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novo Nordisk pay dividends?

Novo Nordisk pays a Semiannually dividend of €0.502 which represents an annual dividend yield of 3.3%. See more information on Novo Nordisk dividends here

What is Novo Nordisk’s EPS estimate?

Novo Nordisk’s EPS estimate is 0.74.

How many shares outstanding does Novo Nordisk have?

Novo Nordisk has 3,390,128,000 shares outstanding.

What happened to Novo Nordisk’s price movement after its last earnings report?

Novo Nordisk reported an EPS of €0.798 in its last earnings report, beating expectations of €0.795. Following the earnings report the stock price went down -4.577%.

Which hedge fund is a major shareholder of Novo Nordisk?

Currently, no hedge funds are holding shares in DE:NOV

Company Description

Novo Nordisk

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk (NOV) Earnings & Revenues

Historic Earnings Reports

NOV Stock 12 Month Forecast

Average Price Target

€61.96

▲(32.78% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"40":"€40","121":"€121","60.25":"€60.3","80.5":"€80.5","100.75":"€100.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":81.7217,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€81.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61.9557662,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€61.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.5498,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€45.55</span>\n  </div></div>","useHTML":true}}],"tickPositions":[40,60.25,80.5,100.75,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.92,51.443207692307695,53.96641538461539,56.48962307692308,59.012830769230774,61.53603846153847,64.05924615384616,66.58245384615384,69.10566153846153,71.62886923076923,74.15207692307692,76.67528461538461,79.1984923076923,{"y":81.7217,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.92,49.92275124615385,50.92550249230769,51.92825373846154,52.931004984615385,53.933756230769234,54.936507476923076,55.939258723076925,56.94200996923077,57.94476121538462,58.94751246153846,59.95026370769231,60.95301495384615,{"y":61.9557662,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.92,48.660753846153845,48.401507692307696,48.14226153846154,47.88301538461538,47.623769230769234,47.36452307692308,47.10527692307692,46.846030769230765,46.586784615384616,46.32753846153846,46.0682923076923,45.809046153846154,{"y":45.5498,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":120.908,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.754,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.351,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.837,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.418,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.367,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.034,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.389,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.666,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.667,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.842,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.168,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >